105年度第二期癌症研究計畫-臺北醫學大學

Medicine & Life Sciences

1. Neoplasms 100%
2. Breast Neoplasms 76%
3. Antibodies 52%
4. Computational Biology 40%
5. Nicotine 34%
6. Brain Neoplasms 32%
7. Micelles 30%
8. Quercetin 29%
9. Magnetic Resonance Imaging 28%
10. varespladib methyl 27%
11. Neoplasm Metastasis 26%
12. Chronic Disease 25%
13. Animal Models 24%
14. Drug Development 24%
15. Genes 24%
16. Systems Biology 20%
17. Nicotinic Receptors 18%
18. Pharmaceutical Preparations 17%
19. Tomography 17%
20. Glioblastoma 16%
21. Drug Resistance 15%
22. Databases 15%
23. Permeability 14%
24. Western Asia 14%
25. 5-chloro-3-tert-butyl-2'-chloro-4'-nitrosalicylanilide 14%
26. Single Nucleotide Polymorphism 14%
27. Colorectal Neoplasms 13%
28. Prostatic Neoplasms 13%
29. Pharmacoepidemiology 13%
30. Breast 13%
31. Growth 13%
32. Referral and Consultation 12%
33. Epitope Mapping 11%
34. Technology 11%
35. Biomarkers 11%
36. Single-Chain Antibodies 11%
37. Medical Informatics 10%
38. Temozolomide 10%
39. Data Mining 10%
40. Triple Negative Breast Neoplasms 10%
41. Gene Expression 10%
42. Growth Factor Receptors 10%
43. Recurrence 9%
44. Therapeutics 9%
45. Protein C 9%
46. Precision Medicine 9%
47. Neoplastic Stem Cells 9%
48. Animals 8%
49. Cigarette Smoking 8%
50. Bacteriophages 8%
51. Taiwan 8%
52. Tumor Biomarkers 8%
53. Chickens 8%
54. DNA Repair 7%
55. Radiologists 7%
56. Epitopes 7%
57. Cell Movement 7%
58. Early Diagnosis 6%
59. University Hospitals 6%
60. Signal Transduction 6%
61. Binding Sites 6%
62. Carcinogenesis 6%
63. Pharmacokinetics 6%
64. Data Analysis 6%
65. Smoking 6%
66. Direction compound 6%
67. Up-Regulation 6%
68. Genotype 6%
69. Ligands 6%
70. Down-Regulation 6%
71. Research Personnel 6%
72. Insulin 5%
73. Western Blotting 5%
74. Aptitude 5%
75. Clinical Trials 5%
76. Antigens 5%
77. Phenotype 5%
78. Cell Line 5%